Mark Alan Goldberg - 31 Mar 2022 Form 4/A - Amendment Insider Report for ImmunoGen, Inc.

Role
Director
Signature
/s/ Renee Lentini, attorney in fact
Issuer symbol
N/A
Transactions as of
31 Mar 2022
Net transactions value
$0
Form type
4/A - Amendment
Filing time
20 Apr 2022, 17:38:30 UTC
Date Of Original Report
04 Apr 2022
Previous filing
07 Mar 2022
Next filing
20 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMGN Deferred Share Unit Award $0 +3,545 +2.7% $0.000000 134,668 31 Mar 2022 Common Stock 3,545 $0.000000 Direct F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis.
F2 The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors.
F3 The deferred share units vest upon issuance.
F4 Due to clerical error, this amendment to Form 4 is being filed to correct the number of DSUs awarded on March 31, 2022 and the number of DSUs beneficially owned following the reported transaction.